1
|
Morschhauser F, Ghosh N, Lossos IS, Palomba ML, Mehta A, Casasnovas O, Stevens D, Katakam S, Knapp A, Nielsen T, McCord R, Salles G. Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. Blood Cancer J 2021; 11:147. [PMID: 34417444 PMCID: PMC8379261 DOI: 10.1038/s41408-021-00539-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 08/04/2021] [Accepted: 08/06/2021] [Indexed: 11/09/2022] Open
Abstract
We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) in an open-label, multicenter phase Ib/II study (BO29562; NCT02631577). An initial 3 + 3 dose-escalation phase to define the recommended phase II dose of lenalidomide was followed by an expansion phase with G-atezo-len induction and maintenance. At final analysis, 38 patients (lenalidomide 15 mg, n = 4; 20 mg, n = 34) had completed the trial. Complete response rate for the efficacy population (lenalidomide 20 mg, n = 32) at end-of-induction was 71.9% (66.7% in double-refractory patients [refractory to rituximab and alkylator] [n = 12]; 50.0% in patients with progressive disease within 24 months of first-line therapy [n = 12]). The 36-month progression-free survival rate was 68.4%. All treated patients had ≥1 adverse event (AE; grade 3-5 AE, 32 patients [84%]; serious AE, 18 patients [47%]; AEs leading to discontinuation of any study drug, 11 patients [29%]). There were 2 fatal AEs (1 merkel carcinoma, 1 sarcomatoid carcinoma; both unrelated to any study drug). The G-atezo-len regimen is effective and tolerable in patients with R/R FL. AEs were consistent with the known safety profile of the individual drugs.
Collapse
Affiliation(s)
- Franck Morschhauser
- University of Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.
| | - Nilanjan Ghosh
- Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA
| | - Izidore S Lossos
- Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| | - M Lia Palomba
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Amitkumar Mehta
- Division of Hematology and Oncology, University of Alabama School of Medicine, Birmingham, AL, USA
| | - Olivier Casasnovas
- Service d'Hématologie Clinique, CHU Dijon Bourgogne - Hôpital François Mitterrand, Dijon, France
| | - Don Stevens
- Norton Cancer Institute, Norton Healthcare, Louisville, KY, USA
| | - Sudhakar Katakam
- Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Andrea Knapp
- Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Tina Nielsen
- Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Ron McCord
- Genentech Inc., South San Francisco, CA, USA
| | - Gilles Salles
- Haematology Department, Université Claude Bernard de Lyon, Lyon University Hospital, Pierre Benite, France
| |
Collapse
|
2
|
Buske C. Follicular lymphoma: treatment guidance in times of change. Ann Oncol 2021; 32:293-294. [PMID: 33434658 DOI: 10.1016/j.annonc.2021.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Accepted: 01/07/2021] [Indexed: 10/22/2022] Open
Affiliation(s)
- C Buske
- Department of Internal Medicine III, Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital, Ulm, Germany.
| |
Collapse
|